|Videos|March 18, 2022
Expert forum on prostate cancer survivorship: Innovations in urinary health
Author(s)Urology Times staff
“I think this is an extremely exciting space,” says Jai Seth, MD, BSc, MSc, FRCS.
Advertisement
Episodes in this series
In this video, Jai Seth, MD, BSc, MSc, discusses innovations in the urinary health space that have helped patients overcome the associated side effects of prostate cancer. This discussion is part of a larger forum on prostate cancer survivorship with Marta Skrodzka, MD, PhD, FEBU, FECSM, FEAA, and Netty Kinsella, RN, MSc, PhD. Skrodzka is a consultant urologist and Seth is a urology consultant at St George’s University Hospital, and Kinsella is a uro-oncology nurse consultant at the Royal Marsden NHS Foundation Trust in London, United Kingdom.
Advertisement
Related to this article
EG110A is an investigational DNA medicine under development for neurogenic detrusor overactivity with urinary incontinence.
Andrew Peterson, MD, discusses the quality-of-life impact of post-cancer incontinence and advances in electronically controlled artificial urinary sphincters.
A recap of the FDA submissions and regulatory decisions in urology from August 2026.
Advertisement
Advertisement
Trending on Urology Times
1
Managing BPH Before Prostate Radiotherapy: Options Compared
2
FAQs: The 2026 AUA Guideline on Medical Management of Kidney Stones
3
FDA grants RMAT designation to EG110A for neurogenic detrusor overactivity
4
PSMA-PET in clinical practice: Juan Gómez Rivas, MD, on barriers to access
5